Correlation of OCT Angiography Vessel Densities and the Early Treatment Diabetic Retinopathy Study Grading Scale

Neesurg S. Mehta; Jessica G. Lee; Lalita Gupta; Davis B. Zhou; Jorge S. Andrade Romo; Maria V. Castanos; Michael Jansen; Toco Yuen Ping Chui; Richard B. Rosen

doi:10.1016/j.oret.2020.11.009

Correlation of OCT Angiography Vessel Densities and the Early Treatment Diabetic Retinopathy Study Grading Scale

Neesurg S. Mehta, Jessica G. Lee, Lalita Gupta, Davis B. Zhou, Jorge S. Andrade Romo, Maria V. Castanos, Michael Jansen, Toco Yuen Ping Chui, Richard B. Rosen

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	714-715
Number of pages	2
Journal	Ophthalmology Retina
Volume	5
Issue number	7
DOIs	https://doi.org/10.1016/j.oret.2020.11.009
State	Published - Jul 2021
Externally published	Yes

Keywords

Diabetic grading scale
Diabetic retinopathy
ETDRS
OCT angiography

Access to Document

10.1016/j.oret.2020.11.009

Cite this

@article{993bd7a4e62b4c41a670a7fc9bdd73c4,

title = "Correlation of OCT Angiography Vessel Densities and the Early Treatment Diabetic Retinopathy Study Grading Scale",

keywords = "Diabetic grading scale, Diabetic retinopathy, ETDRS, OCT angiography",

author = "Mehta, {Neesurg S.} and Lee, {Jessica G.} and Lalita Gupta and Zhou, {Davis B.} and {Andrade Romo}, {Jorge S.} and Castanos, {Maria V.} and Michael Jansen and {Ping Chui}, {Toco Yuen} and Rosen, {Richard B.}",

note = "Funding Information: The author(s) have made the following disclosure(s): R.B.R.: Consultant – OptoVue, Boehringer-Ingelheim, Astellas, Genentech-Roche, NanoRetina, OD-OS, Regeneron, Bayer; Equity owner – Opticology, Guardion Supported by the National Eye Institute , National Institutes of Health, Bethesda, Maryland (grant no.: R01EY027301). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional funding for this research was provided by the New York Eye and Ear Infirmary Research Foundation , New York, New York, and the Marrus Family Foundation, New York, New York. The sponsors and funding organizations had no role in the design or conduct of this research. Funding Information: The author(s) have made the following disclosure(s): R.B.R.: Consultant – OptoVue, Boehringer-Ingelheim, Astellas, Genentech-Roche, NanoRetina, OD-OS, Regeneron, Bayer; Equity owner – Opticology, Guardion Supported by the National Eye Institute, National Institutes of Health, Bethesda, Maryland (grant no.: R01EY027301). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional funding for this research was provided by the New York Eye and Ear Infirmary Research Foundation, New York, New York, and the Marrus Family Foundation, New York, New York. The sponsors and funding organizations had no role in the design or conduct of this research. Obtained funding: Lee",

year = "2021",

month = jul,

doi = "10.1016/j.oret.2020.11.009",

language = "English",

volume = "5",

pages = "714--715",

journal = "Ophthalmology Retina",

issn = "2468-6530",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Correlation of OCT Angiography Vessel Densities and the Early Treatment Diabetic Retinopathy Study Grading Scale

AU - Mehta, Neesurg S.

AU - Lee, Jessica G.

AU - Gupta, Lalita

AU - Zhou, Davis B.

AU - Andrade Romo, Jorge S.

AU - Castanos, Maria V.

AU - Jansen, Michael

AU - Ping Chui, Toco Yuen

AU - Rosen, Richard B.

N1 - Funding Information: The author(s) have made the following disclosure(s): R.B.R.: Consultant – OptoVue, Boehringer-Ingelheim, Astellas, Genentech-Roche, NanoRetina, OD-OS, Regeneron, Bayer; Equity owner – Opticology, Guardion Supported by the National Eye Institute , National Institutes of Health, Bethesda, Maryland (grant no.: R01EY027301). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional funding for this research was provided by the New York Eye and Ear Infirmary Research Foundation , New York, New York, and the Marrus Family Foundation, New York, New York. The sponsors and funding organizations had no role in the design or conduct of this research. Funding Information: The author(s) have made the following disclosure(s): R.B.R.: Consultant – OptoVue, Boehringer-Ingelheim, Astellas, Genentech-Roche, NanoRetina, OD-OS, Regeneron, Bayer; Equity owner – Opticology, Guardion Supported by the National Eye Institute, National Institutes of Health, Bethesda, Maryland (grant no.: R01EY027301). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional funding for this research was provided by the New York Eye and Ear Infirmary Research Foundation, New York, New York, and the Marrus Family Foundation, New York, New York. The sponsors and funding organizations had no role in the design or conduct of this research. Obtained funding: Lee

PY - 2021/7

Y1 - 2021/7

KW - Diabetic grading scale

KW - Diabetic retinopathy

KW - ETDRS

KW - OCT angiography

UR - http://www.scopus.com/inward/record.url?scp=85104124538&partnerID=8YFLogxK

U2 - 10.1016/j.oret.2020.11.009

DO - 10.1016/j.oret.2020.11.009

M3 - Article

C2 - 33227562

AN - SCOPUS:85104124538

SN - 2468-6530

VL - 5

SP - 714

EP - 715

JO - Ophthalmology Retina

JF - Ophthalmology Retina

IS - 7

ER -